KAYLA WHITLEY: Open Payments
NPI 1952050312 · GRAY, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,419 in 62 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $1,325 · 2025 $1,419
Food & beverage: $1,385Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 18 | $335 |
| BioCryst US Sales Co., LLC | 6 | $169 |
| Regeneron Healthcare Solutions, Inc. | 5 | $140 |
| GENZYME CORPORATION | 4 | $115 |
| GlaxoSmithKline, LLC. | 6 | $109 |
| Novartis Pharmaceuticals Corporation | 4 | $104 |
| CSL Behring | 5 | $99 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $90 |
| Genentech USA, Inc. | 3 | $80 |
| Amgen Inc. | 2 | $60 |
Products named: DUPIXENT, FASENRA, ORLADEYO, XOLAIR, NEFFY, NUCALA, AIRSUPRA, Prolastin-C Liquid.
Industry payments across GA — which companies pay providers there.
